ANDROGEN RECEPTOR SIGNALING IN HUMAN CORPUS CAVERNOSUM IS NOT DEPENDENT UPON HALF-LIFE OF TESTOSTERONE THERAPY

Abstract

Testosterone therapy can be administered either with intramuscular substitution of long-acting TRT (testosterone enanthate and testosterone cypionate) and short-acting nasal gel T (Natesto) with varying half-lives (1,2). What remains unclear is whether there are varying levels of androgen receptor signaling within the tissue with varying levels of serum testosterone. We hypothesized that men who receive testosterone therapy with eugonadal levels of serum testosterone regardless of the half-life of the testosterone preparation will have similar androgen receptor signaling within the tissue.